FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0

Ronald Boellaard, Mike J O'Doherty, Wolfgang A Weber, Felix M Mottaghy, Markus N Lonsdale, Sigrid G Stroobants, Wim J G Oyen, Joerg Kotzerke, Otto S Hoekstra, Jan Pruim, Paul K Marsden, Klaus Tatsch, Corneline J Hoekstra, Eric P Visser, Bertjan Arends, Fred J Verzijlbergen, Josee M Zijlstra, Emile F I Comans, Adriaan A Lammertsma, Anne M Paans, Antoon T Willemsen, Thomas Beyer, Andreas Bockisch, Cornelia Schaefer-Prokop, Dominique Delbeke, Richard P Baum, Arturo Chiti, Bernd J Krause, Ronald Boellaard, Mike J O'Doherty, Wolfgang A Weber, Felix M Mottaghy, Markus N Lonsdale, Sigrid G Stroobants, Wim J G Oyen, Joerg Kotzerke, Otto S Hoekstra, Jan Pruim, Paul K Marsden, Klaus Tatsch, Corneline J Hoekstra, Eric P Visser, Bertjan Arends, Fred J Verzijlbergen, Josee M Zijlstra, Emile F I Comans, Adriaan A Lammertsma, Anne M Paans, Antoon T Willemsen, Thomas Beyer, Andreas Bockisch, Cornelia Schaefer-Prokop, Dominique Delbeke, Richard P Baum, Arturo Chiti, Bernd J Krause

Abstract

The aim of this guideline is to provide a minimum standard for the acquisition and interpretation of PET and PET/CT scans with [18F]-fluorodeoxyglucose (FDG). This guideline will therefore address general information about[18F]-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET/CT) and is provided to help the physician and physicist to assist to carrying out,interpret, and document quantitative FDG PET/CT examinations,but will concentrate on the optimisation of diagnostic quality and quantitative information.

References

    1. Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumour imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–895.
    1. Krause BJ, Beyer T, Bockisch A, Delbeke D, Kotzerke J, Minkov V, et al. FDG-PET/CT in oncology. German guideline. Nuklearmedizin. 2007;46:291–301.
    1. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–2333. doi: 10.1007/s00259-008-0874-2.
    1. Bourguet P, Blanc-Vincent MP, Boneu A, Bosquet L, Chauffert B, Corone C, et al. Summary of the standards, options and recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDG-PET scanning) in oncology (2002) Br J Cancer. 2003;89(Suppl 1):S84–91. doi: 10.1038/sj.bjc.6601088.
    1. Coleman RE, Delbeke D, Guiberteau MJ, Conti PS, Royal HD, Weinreb JC, et al. Concurrent PET/CT with an integrated imaging system: Intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance. J Nucl Med. 2005;46:1225–1239.
    1. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of F-18-FDG PET in oncology. J Nucl Med. 2008;49:480–508. doi: 10.2967/jnumed.107.047787.
    1. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in lymphoma. J Clin Oncol. 2007;25:571–578. doi: 10.1200/JCO.2006.08.2305.
    1. Lammertsma AA, Hoekstra CJ, Giaccone G, Hoekstra OS. How should we analyse FDG PET studies for monitoring tumour response? Eur J Nucl Med Mol Imaging. 2006;33(Suppl 1):16–21. doi: 10.1007/s00259-006-0131-5.
    1. Miller JC, Fischman AJ, Aquino SL, Blake MA, Thrall JH, Lee SI. FDG-PET CT for tumour imaging. J Am Coll Radiol. 2007;4:256–259. doi: 10.1016/j.jacr.2006.10.011.
    1. Schelbert HR, Hoh CK, Royal HD, Brown M, Dahlbom MN, Dehdashti F, et al. Procedure guideline for tumour imaging using fluorine-18-FDG. Society of Nuclear Medicine. J Nucl Med. 1998;39:1302–1305.
    1. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of F-18-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med. 2006;47:1059–1066.
    1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumours. J Nucl Med. 2009;50(Suppl 1):122S–1250. doi: 10.2967/jnumed.108.057307.
    1. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–1782. doi: 10.1016/S0959-8049(99)00229-4.
    1. Zijlstra JM, Comans EF, van Lingen A, Hoekstra OS, Gundy CM, Coebergh JW, et al. FDG PET in lymphoma: the need for standardization of interpretation. An observer variation study. Nucl Med Commun. 2007;28:798–803. doi: 10.1097/MNM.0b013e3282eff2d5.
    1. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50(Suppl 1):11S–20. doi: 10.2967/jnumed.108.057182.
    1. Lowe VJ, Delong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med. 1995;36:883–887.
    1. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol Clin North Am. 2005;43:189–204. doi: 10.1016/j.rcl.2004.09.006.
    1. Bastiaannet E, Groen H, Jager PL, Cobben DCP, van der Graaf WTA, Vaalburg W, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev. 2004;30:83–101. doi: 10.1016/j.ctrv.2003.07.004.
    1. Borst GR, Belderbos JSA, Boellaard R, Comans EFI, de Jaeger K, Lammertsma AA, et al. Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer. 2005;41:1533–1541. doi: 10.1016/j.ejca.2005.03.026.
    1. Erdi YE. The use of PET for radiotherapy. Curr Med Imaging Rev. 2007;3:3–16. doi: 10.2174/157340507779940291.
    1. Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ. Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. Cancer. 2007;110:1654–1664. doi: 10.1002/cncr.22979.
    1. Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van Tinteren H, Postmus PE, et al. Prognostic relevance of response evaluation using [F-18]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol. 2005;23:8362–8370. doi: 10.1200/JCO.2005.01.1189.
    1. Larson SM, Schwartz LH. 18F-FDG PET as a candidate for “qualified biomarker”: functional assessment of treatment response in oncology. J Nucl Med. 2006;47:901–903.
    1. Vansteenkiste JF, Stroobants SG. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology. Eur Respir J. 2001;17:802–820. doi: 10.1183/09031936.01.17408020.
    1. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46:983–995.
    1. Borst G, Belderbos J, Boellaard R, Comans E, de Jaeger K, Lammertsma A, et al. Prognostic significance of the 18FDG-PET standardized uptake value for inoperable non-small cell lung cancer patients after high-dose radiotherapy. Lung Cancer. 2005;49:S50. doi: 10.1016/S0169-5002(05)80279-X.
    1. Dai KS, Tai DY, Ho P, Chen CC, Peng WC, Chen ST, et al. Accuracy of the EasyTouch blood glucose self-monitoring system: a study of 516 cases. Clin Chim Acta. 2004;349:135–141. doi: 10.1016/j.cccn.2004.06.010.
    1. ICRP Radiation dose to patients from radiopharmaceuticals. Addendum 3 to ICRP Publication 53. ICRP Publication 106. Approved by the Commission in October 2007. Ann ICRP. 2008;38:1–197.
    1. Lassmann M, Biassoni L, Monsieurs M, Franzius C. The new EANM paediatric dosage card: additional notes with respect to F-18. Eur J Nucl Med Mol Imaging. 2008;35:1666–1668. doi: 10.1007/s00259-008-0799-9.
    1. Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med. 2004;45:1519–1527.
    1. Masuda Y, Kondo C, Matsuo Y, Uetani M, Kusakabe K. Comparison of imaging protocols for 18F-FDG PET/CT in overweight patients: optimizing scan duration versus administered dose. J Nucl Med. 2009;50:844–848. doi: 10.2967/jnumed.108.060590.
    1. Boellaard R, van Lingen A, van Balen SCM, Lammertsma AA. Optimization of attenuation correction for positron emission tomography studies of thorax and pelvis using count-based transmission scans. Phys Med Biol. 2004;49:N31–38. doi: 10.1088/0031-9155/49/4/N01.
    1. Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, et al. Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging. 2007;34:392–404. doi: 10.1007/s00259-006-0224-1.
    1. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;1–4.
    1. Krak NC, Boellaard R, Hoekstra OS, Twisk JWR, Hoekstra CJ, Lammertsma AA. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. 2005;32:294–301. doi: 10.1007/s00259-004-1566-1.
    1. Geets X, Lee JA, Bol A, Lonneux M, Gregoire V. A gradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nucl Med Mol Imaging. 2007;34:1427–1438. doi: 10.1007/s00259-006-0363-4.
    1. van Dalen JA, Hoffmann AL, Dicken V, Vogel WV, Wiering B, Ruers TJ, et al. A novel iterative method for lesion delineation and volumetric quantification with FDG PET. Nucl Med Commun. 2007;28:485–493. doi: 10.1097/MNM.0b013e328155d154.
    1. Hatt M, Lamare F, Boussion N, Turzo A, Collet C, Salzenstein F, et al. Fuzzy hidden Markov chains segmentation for volume determination and quantitation in PET. Phys Med Biol. 2007;52:3467–3491. doi: 10.1088/0031-9155/52/12/010.
    1. Greuter HN, Boellaard R, van Lingen A, Franssen EJ, Lammertsma AA. Measurement of 18F-FDG concentrations in blood samples: comparison of direct calibration and standard solution methods. J Nucl Med Technol. 2003;31:206–209.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe